Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: A systematic review and a meta-analysis

Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8, Rome 00168, Italy.
Clinical neurology and neurosurgery (Impact Factor: 1.25). 09/2011; 113(10):823-9. DOI: 10.1016/j.clineuro.2011.09.004
Source: PubMed

ABSTRACT This study was designed to review the diagnostic performance of iodine-123-metaiodobenzylguanidine (MIBG) scintigraphy in differential diagnosis between Parkinson's disease (PD) and multiple-system atrophy (MSA).
A comprehensive computer literature search of studies published through March 2011 regarding MIBG scintigraphy in patients with PD and MSA was performed in PubMed/MEDLINE and Embase databases. Only studies in which MIBG scintigraphy was performed for differential diagnosis between PD and MSA were selected. Pooled sensitivity and specificity of MIBG scintigraphy were presented with a 95% confidence interval (CI). The area under the ROC curve was calculated to measure the accuracy of MIBG scintigraphy in differential diagnosis between PD and MSA.
Ultimately, we identified 12 studies comprising a total of 1226 patients (593 patients with PD, 117 patients with other Lewy body disease, 129 patients with MSA, and 387 patients with other diseases). The pooled sensitivity of MIBG scintigraphy to detect PD was 89% (95% CI: 86-91%); the pooled specificity of MIBG scintigraphy to discriminate between PD and MSA was 77% (95% CI: 68-84%). The area under the ROC curve was 0.93.
MIBG scintigraphy is an accurate test for PD detection and differential diagnosis between PD and MSA; this method shows high sensitivity and adequate specificity in this field. Nevertheless, possible causes of false negative and false positive findings should be considered when interpreting the scintigraphic results.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of multiple system atrophy (MSA) and its differentiation from Parkinson disease (PD) can be extremely challenging, particularly in early stages of disease. Both structural and functional imaging studies may be helpful for making the diagnosis, and may potentially be a means of monitoring disease progression. MRI may show distinctive patterns of atrophy and signal changes in MSA, such as the “hot-cross bun” sign and the hyperintense putaminal rim sign, which are relatively specific but have low sensitivity. Diffusivity may be particularly helpful in differentiating MSA from PD and appears to change over time, although the correlation with changes in motor dysfunction is uncertain. Diffusion weighted imaging can also reliably separate MSA from PSP by detecting alterations in the middle cerebellar peduncle. Volumetry can be used to detect characteristic patterns of atrophy. Alterations in spectroscopic patterns and abnormal iron deposition have also been reported. PET or SPECT measures of striatal dopamine innervations are abnormal in MSA and PD, addition of dopamine D2 receptor imaging (preserved in PD) may be helpful in differentiating the two. However, fluorodeoxyglucose (FDG) PET which show different characteristic metabolic networks in the two conditions that change with disease progression is probably more useful. Functional imaging can also be used to detect changes in cholinergic innervation in MSA, and to study neuroinflammation. Imaging of cardiac sympathetic innervation can also differentiate between PD and MSA and may be underutilized for this purpose.This article is protected by copyright. All rights reserved.
    08/2014; 2(6). DOI:10.1111/ncn3.125
  • [Show abstract] [Hide abstract]
    ABSTRACT: Central or peripheral neurological disorders can manifest with autonomic failure or autonomic hyperactivity, which may affect the sympathetic, parasympathetic and/or enteric nervous systems. Disorders causing autonomic failure can be classified according to the presence or absence of associated neurological manifestations, such as peripheral neuropathy or parkinsonism, and their temporal profile (acute or subacute, chronic progressive, static, or episodic). A systematic approach allows focused evaluation to detect treatable, potentially disabling or life-threatening conditions. Subacute isolated autonomic failure affecting sympathetic, parasympathetic and enteric nervous system function, in various combinations, occurs in autoimmune autonomic ganglionopathy, which might be the first manifestation of an underlying neoplasm. Autonomic failure can be an important feature of several types of peripheral neuropathy, including sensorimotor peripheral neuropathies, sensory ganglionopathy, and distal painful peripheral neuropathies. Progressive autonomic failure occurs in neurodegenerative synucleinopathies such as multiple system atrophy and Lewy body disorders. Autonomic failure may also occur in hereditary leukoencephalopathies or prion disorders. This Review outlines the clinical approach to patients with generalized autonomic failure, focusing predominantly on classification and diagnosis, but also touching briefly on treatment and management.
    Nature Reviews Neurology 05/2014; 10(7). DOI:10.1038/nrneurol.2014.88 · 14.10 Impact Factor
  • Source
    Der Nuklearmediziner 01/2012; 35:109-123. DOI:10.1055/s-0032-1312637


Available from
May 20, 2014